MGD013 dual-affinity re-targeting (DART)
MGD013 dual-affinity re-targeting (DART) Uses, Dosage, Side Effects, Food Interaction and all others data.
MGD013 dual-affinity re-targeting (DART) is under investigation in clinical trial NCT04082364 (Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/gej Cancer (MAHOGANY)).
| Trade Name | MGD013 dual-affinity re-targeting (DART) |
| Generic | Tebotelimab |
| Tebotelimab Other Names | MGD013 dual-affinity re-targeting (DART) |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here MGD013 dual-affinity re-targeting (DART)
